Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system

Methotrexate (MTX) is an essential anti-rheumatic drug used to treat rheumatoid arthritis (RA). Prevention or management of adverse reactions, including interstitial lung disease (ILD), hepatotoxicity, myelosuppression, and infection, remains fundamental for safe MTX therapy. Using the Food and Drug...

Full description

Bibliographic Details
Main Authors:	Kenji Onda, Takeshi Honma, Koichi Masuyama
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Pharmacology
Subjects:	methotrexate FAERS database folic acid TNFalpha inhibitor interstitial lung disease hepatotoxicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1030832/full

Similar Items

Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen
by: Finola M. Bruins, et al.
Published: (2022-06-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms
by: Payal Rana, et al.
Published: (2021-12-01)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022-11-01)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
by: Yang Bai, et al.
Published: (2023-09-01)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
by: Long Meng, et al.
Published: (2021-02-01)

EFFECT OF FOLIC ACID ON SOME PHYSIOLOGICAL PARAMETERS IN FEMALE RABBITS TREATED WITH METHOTREXATE
by: K. A. Hadi, et al.
Published: (2023-06-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
by: Qiang Guo, et al.
Published: (2022-11-01)

Methotrexate Hepatotoxicity; the Danger Not to Be Ignored
by: M Baghbanian, et al.
Published: (2013-06-01)

Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
by: Eugene Jeong, et al.
Published: (2022-07-01)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2021-04-01)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
by: Renjun Yang, et al.
Published: (2022-01-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024-01-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
by: Shu Y, et al.
Published: (2022-06-01)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023-12-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2022-09-01)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
by: Xiujuan Gui, et al.
Published: (2023-10-01)

Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system
by: Hongxia Shi, et al.
Published: (2024-04-01)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
by: Yinghong Zhai, et al.
Published: (2021-09-01)

Species differences in methotrexate-induced hepatotoxicity and nephrotoxicity: Rabbits resist methotrexate nephrotoxicity
by: Jawad H. Ahmed
Published: (2016-06-01)

Analysis of the various schemes efficiency of methotrexate use in psoriasis treatment
by: Kruglova L.S., et al.
Published: (2017-09-01)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
by: Linlin Tang, et al.
Published: (2024-02-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data
by: Guowen Feng, et al.
Published: (2023-01-01)

Folate supplementation in patients with psoriasis treated with methotrexate – effect on safety and efficacy
by: Magdalena Żychowska, et al.
Published: (2014-10-01)

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
by: Wei Chen, et al.
Published: (2024-02-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

Psoriatic flare after the concomitant administration of L-methylfolate and methotrexate
by: Roya S. Nazarian, BA, et al.
Published: (2017-01-01)

Effects of Pomegranate Seed and Peel Methanolic Extracts on Methotrexate-Induced Hepatotoxicity in Rats
by: Farideh Doostan, et al.
Published: (2019-06-01)